Isofol is a cancer research company based in Gothenburg, where i have been executive chairman since 2012. It was started by the inventor, Professor Bengt Gustavsson and my good friend and the previous chairman Lars Lind and i took over as chairman, when it expanded. isofol is in clinical trials with a new cancer drug mainly for colorectal cancer.
Isofol has from its inception until now mainly been financed by a business angel network build around Lars and a number of his colleagues and raised a couple of hundred million SEK (Swedish Krona). But now we are planning to enter a new era with a pivotal clinical trial that hopefully will lead to drug approval. And the resources from the business angel network wasn’t any longer enough to finance the continued development.
So during a few very hectic months in beginning of 2017 and towards the end of 2016, Anders Rabbe, CEO and I as chairman raised SEK 430m from both Swedish and international investors.
And in beginning of April we took the company public on the Stockholm Nasdaq Exchange. A new era had started for Isofol.
Everyone of the board and management and several family members took part and afterwards we were offered a tour of the old town of Stockholm (Gamla Stan) and had lunch at Fem Små Hus and later a dinner on Djurgården, an island in central Stockholm.
